| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Aurora kinase B |
|---|
| Ligand | BDBM50535113 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1929868 (CHEMBL4433044) |
|---|
| IC50 | 63±n/a nM |
|---|
| Citation |  Garton, NS; Barker, MD; Davis, RP; Douault, C; Hooper-Greenhill, E; Jones, E; Lewis, HD; Liddle, J; Lugo, D; McCleary, S; Preston, AGS; Ramirez-Molina, C; Neu, M; Shipley, TJ; Somers, DO; Watson, RJ; Wilson, DM Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors. Bioorg Med Chem Lett26:4606-4612 (2016) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Aurora kinase B |
|---|
| Name: | Aurora kinase B |
|---|
| Synonyms: | AIK2 | AIM-1 | AIM1 | AIRK2 | ARK2 | AURKB | AURKB_HUMAN | Aurora B kinase (aurB) | Aurora B-INCENP | Aurora kinase 2 | Aurora kinase B (AURKB) | Aurora-related kinase 2 | STK-1 | STK1 | STK12 | STK5 | Serine/threonine-protein kinase aurora B |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 39327.72 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q96GD4 |
|---|
| Residue: | 344 |
|---|
| Sequence: | MAQKENSYPWPYGRQTAPSGLSTLPQRVLRKEPVTPSALVLMSRSNVQPTAAPGQKVMEN
SSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEH
QLRREIEIQAHLHHPNILRLYNYFYDRRRIYLILEYAPRGELYKELQKSCTFDEQRTATI
MEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHAPSLRRKTMCGTLDYL
PPEMIEGRMHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPASVPMGA
QDLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA
|
|
|
|---|
| BDBM50535113 |
|---|
| n/a |
|---|
| Name | BDBM50535113 |
|---|
| Synonyms: | CHEMBL4473150 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C17H18F2N6O |
|---|
| Mol. Mass. | 360.3612 |
|---|
| SMILES | Cn1cc(cn1)-c1cc2nccnc2c(OCC2CNCC(F)(F)C2)n1 |
|---|
| Structure | 
|
|---|
Search and Browse
